Keyword: Kalydeco

Vertex is in the early stages of its triple combo launch Trikafta, which the company believes can treat up to 90% of cystic fibrosis patients.

The triple combo era in cystic fibrosis, thanks to Vertex and an FDA green light for its next big blockbuster hope, Trikafta.

England’s National Health Service made its "final" offer to cover Vertex's cystic fibrosis drugs, but the company still isn't happy.

Vertex CEO Jeffrey Leiden took his fight over CF drug prices to U.K. Prime Minister Theresa May, urging her to step in.

Vertex has cancelled plans to test an investigational triple combo at several sites in France.

Vertex is ready to do some deals, CEO Jeffrey Leiden said Monday, and he's shopping beyond cystic fibrosis. CRISPR, for instance.

Stepped-up competition and insurer pushback aren't going away, but some are better able to handle it—and could emerge as top M&A targets.

Last year, the FDA nixed Vertex’s bid to expand Kalydeco to patients with specific mutations in the CFTR gene. On Wednesday, though, the drugmaker finally got what it wanted.

Vertex started tying compensation more closely to company performance last year, and it showed in CEO Jeff Leiden's 2016 pay.